Medicare Part D enrollees who rely on Ozempic to manage type 2 diabetes will pay $274 for a 30-day supply starting January 1, 2027, a 71% reduction from the drug’s current price under the program. The Centers for Medicare & Medicaid Services (CMS) set that figure through the Medicare Drug Price Negotiation Program, one of 15 drugs that received new maximum fair prices covering cancer and chronic disease treatments. For the millions of seniors filling Ozempic prescriptions each month, the price drop represents the single largest pocketbook change the negotiation program has delivered for a diabetes medication.
Why a 71% Ozempic Price Cut Changes Senior Spending in 2027
The $274 maximum fair price, or MFP, applies to every Medicare Part D claim for Ozempic once the new rate kicks in at the start of 2027. CMS publishes the negotiated prices and National Drug Codes through downloadable datasets that list a single negotiated price for a 30-day equivalent supply along with per-unit and per-package figures. That transparency means Part D plans, pharmacies, and beneficiaries can all see the exact ceiling price months before it takes effect and can begin adjusting formularies, preferred pharmacy networks, and budgeting assumptions ahead of the change.
The practical consequence for high-cost users is direct. Seniors whose current copays or coinsurance are pegged to the drug’s list price will see their cost-sharing recalculated against the lower MFP. Those who today spend the most out of pocket on Ozempic stand to gain the most in absolute dollar terms, particularly beneficiaries who routinely hit the catastrophic phase of Part D coverage. Because the negotiated price becomes the reference point for plan payments and patient cost-sharing, even modest percentage coinsurance can translate into substantial monthly savings when applied to a sharply lower base price.
One testable question is whether that relief will push more beneficiaries toward 90-day fills, a pattern that would show up in 2027 and 2028 claims data when sorted by prior out-of-pocket spending. Beneficiaries who previously rationed doses or delayed refills because of cost pressure would have the strongest financial incentive to shift to longer supply intervals once the new price arrives. If plans respond by steering members to mail-order or extended supplies, reduced refill gaps could translate into better adherence for a drug that plays a central role in glycemic control and cardiovascular risk reduction for many older adults with type 2 diabetes.
The savings also interact with other recent Part D changes, including the redesign that caps annual out-of-pocket spending. For seniors who use multiple high-cost medicines, the lower Ozempic price could delay when they reach the cap or reduce the number of months in which they face high coinsurance. That combined effect will be most visible among beneficiaries with complex chronic conditions who rely on several of the drugs subject to negotiated prices.
How CMS, Novo Nordisk, and the Negotiation Timeline Produced the $274 Figure
The Department of Health and Human Services selected Ozempic, along with related products such as Rybelsus and Wegovy, for the second cycle of Medicare drug price negotiations. According to a CMS announcement, that cycle added 15 additional drugs to the negotiation program as part of a continued effort to lower prescription costs for Medicare beneficiaries. Negotiations with manufacturers were conducted during 2025, with final prices scheduled to take effect in 2027 after CMS completed its review and issued formal MFP determinations.
CMS has stated that Novo Nordisk, Ozempic’s manufacturer, elected to participate in the process, a decision that was not guaranteed at the outset. Manufacturers faced a choice between entering negotiations or potentially withdrawing their products from Medicare and Medicaid coverage entirely, a step that would have sharply limited access for older adults and low-income patients. By opting in, Novo Nordisk agreed to submit data, respond to CMS offers, and ultimately accept an MFP that is substantially below the current Part D price.
Under the negotiation statute, CMS evaluates a range of factors when setting an MFP, including clinical benefit, unmet medical need, and the availability of therapeutic alternatives. The agency publishes drug-by-drug explanations that describe its rationale for each negotiated figure, drawing on clinical trial results, real-world evidence, and manufacturer-submitted cost and revenue information. What CMS has not released publicly are the specific counter-offer details or meeting records from the negotiation sessions themselves, so the precise give-and-take that produced the $274 number remains confidential.
Novo Nordisk has not issued detailed public statements through CMS channels about expected revenue effects or any planned supply adjustments tied to the lower price. That leaves open questions about how the company will balance reduced Medicare unit prices with potential volume changes if more seniors initiate or remain on Ozempic therapy once cost barriers fall. Investors and health policy analysts are likely to watch 2027 prescription trends closely to see whether higher utilization offsets some of the revenue impact of the negotiated price.
Where Ozempic Fits in the Broader Negotiation Program
The 15 drugs that received negotiated prices span treatments for cancer, cardiovascular disease, autoimmune disorders, and other chronic conditions. A CMS press release emphasizes that all of the new MFPs take effect on January 1, 2027, creating a synchronized shift in Part D pricing for some of the program’s highest-spend medicines. Ozempic’s 71% reduction stands out within that group because of the large number of Medicare beneficiaries with diabetes and obesity-related comorbidities who are candidates for treatment.
For policymakers, Ozempic will serve as an early test case of how negotiated prices affect both household budgets and clinical outcomes for a widely used chronic disease drug. If the $274 MFP leads to measurable improvements in adherence, fewer hospitalizations, or slower progression of diabetes-related complications, it could strengthen the case for extending or expanding Medicare’s negotiation authority in future years. For now, seniors who depend on Ozempic can mark 2027 as the year when one of their most expensive prescriptions becomes significantly more affordable.
Free for readers: The free Retirement Shield newsletter sends plain-English help keeping more of your money in retirement — the scams to dodge, the benefits you’re owed, and what’s changing with Social Security and Medicare, a couple times a week. Get the free newsletter.
